Leonabio Inc (LONA) Stock Price, Quote & News

Company Profile

LeonaBio, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name...

Industry: Biotechnology

Sector: Healthcare

Phone: 425 620 8501

Website: leonabio.com

Address:

18706 North Creek Parkway, Suite 104, Bothell, United States

EMILYXCap Mar. 19 at 5:30 PM

$LONA very low attention tape and that is exactly where asymmetry can hide before a pop

0 · Reply

newyork1979 Mar. 18 at 7:16 PM

TAOP could easily 3X from here - 900k FLoat with no dilution - Robotics / AI merger coming with a company that has HUGE customers like mcdonals/KFC/Starbucks - TAOP is only valued around $12M , very undervalued. - Shorts are trapped and will be forced to buyback all their shares which will cause a Mother of all short squeezes. $GSIW $TRNR $ZNB $LONA $MSTP WW

0 · Reply

Stackdoe101 Mar. 18 at 2:17 PM

$LONA

0 · Reply

Spicy_Trade Mar. 18 at 2:15 PM

SpicyTrade LeonaBio, Inc. ( $LONA ) daily stock analysis https://youtu.be/s1knnYRMF5w?si=Ka0Y8K7hpC7D3CBE

0 · Reply

FoxyDreams Mar. 17 at 11:49 PM

}@SqueezeSharkie is operating on a whole different level, easily ahead of 90% of traders on this platform. If you’re not following yet, you’re missing out. It takes 2 seconds and it’s completely free. 💎 $EDSA $LONA $KRKR $LNZA ^ on watch

0 · Reply

FoxyDreams Mar. 17 at 8:56 PM

>@SqueezeSharkie is on another level, outperforming 90% of traders on this platform. If you’re not following yet, you’re leaving value on the table. Takes 2 seconds and it’s free💎 $INLF $LONA $ISPR $OCG >> on close watch

0 · Reply

topstockalerts Mar. 17 at 8:31 PM

Top Gainers PT2 $INLF $KRKR $LONA $LMNX $ISPR

0 · Reply

Jteee Mar. 17 at 7:52 PM

$LONA flying high

0 · Reply

Tradebub Mar. 17 at 7:49 PM

$LONA

0 · Reply

SebNo1234 Mar. 17 at 7:40 PM

$LONA looks wonderful😎🚀🍀👍🚀🚀

0 · Reply

LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer

Dec 18, 2025, 2:17 PM EST - 3 months ago

Why Is Athira Pharma Stock Spiking After Breast Cancer Asset Acquisition?

Dec 18, 2025, 1:09 PM EST - 3 months ago

Athira Pharma recovers from Alzheimer's failure with breast cancer pivot and $90M investment

Dec 18, 2025, 7:02 AM EST - 3 months ago

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

Sep 11, 2025, 9:00 AM EDT - 6 months ago

Athira Pharma Announces Reverse Stock Split

May 13, 2025, 11:00 AM EDT - 11 months ago

Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit

May 9, 2025, 4:05 PM EDT - 11 months ago

Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates

Feb 27, 2025, 4:05 PM EST - 1 year ago

Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates

Jan 7, 2025, 5:15 PM EST - 1 year ago

Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct

Dec 6, 2024, 5:30 PM EST - 1 year ago

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND

Nov 7, 2024, 4:05 PM EST - 1 year ago

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

Sep 17, 2024, 11:59 AM EDT - 1 year ago

Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring

Sep 17, 2024, 9:00 AM EDT - 1 year ago

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

Sep 4, 2024, 8:48 AM EDT - 1 year ago

Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks

Sep 3, 2024, 4:13 PM EDT - 1 year ago

Athira Pharma's Alzheimer's drug fails in mid-to-late stage trial

Sep 3, 2024, 4:01 PM EDT - 1 year ago

Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease

Aug 1, 2024, 4:05 PM EDT - 1 year ago

Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates

Jul 31, 2024, 8:05 AM EDT - 1 year ago

Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology at the Alzheimer's Association International Conference (AAIC) 2024

Jun 12, 2024, 7:00 AM EDT - 1 year ago

Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients

May 29, 2024, 7:00 AM EDT - 1 year ago

Athira Pharma to Participate in Upcoming June Conferences

May 17, 2024, 5:00 PM EDT - 2 years ago

Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action

May 15, 2024, 4:05 PM EDT - 2 years ago

Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates

May 2, 2024, 7:00 AM EDT - 2 years ago

Athira Pharma to Participate in Upcoming May Conferences

Apr 15, 2024, 7:00 AM EDT - 2 years ago

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

Apr 11, 2024, 7:00 AM EDT - 2 years ago

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease

Apr 3, 2024, 7:00 AM EDT - 2 years ago

Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting

Mar 8, 2024, 7:00 AM EST - 2 years ago

Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD™ 2024 International Conference

Feb 22, 2024, 4:05 PM EST - 2 years ago

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates

Feb 8, 2024, 4:02 PM EST - 2 years ago

Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Jan 8, 2024, 7:00 AM EST - 2 years ago

Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update

Jan 3, 2024, 7:00 AM EST - 2 years ago

Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease

Dec 12, 2023, 7:00 AM EST - 2 years ago

Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies

Nov 29, 2023, 7:00 AM EST - 2 years ago

Athira Pharma to Participate in Sidoti December Small Cap Investor Conference

Nov 15, 2023, 8:15 AM EST - 2 years ago

Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease

Nov 8, 2023, 7:00 AM EST - 2 years ago

Athira Pharma to Participate in Jefferies London Healthcare Conference

Oct 5, 2023, 4:30 PM EDT - 2 years ago

Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Sep 19, 2023, 7:00 AM EDT - 2 years ago

Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

Aug 10, 2023, 4:05 PM EDT - 2 years ago

Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates

Jul 17, 2023, 7:00 AM EDT - 2 years ago

Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer's Disease

Jul 6, 2023, 7:00 AM EDT - 2 years ago

Athira Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2023

May 22, 2023, 7:00 AM EDT - 3 years ago

Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer

May 8, 2023, 7:00 AM EDT - 3 years ago

Athira Pharma to Participate in Upcoming May Investor Conferences

Apr 25, 2023, 4:01 PM EDT - 3 years ago

Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting

Apr 11, 2023, 7:00 AM EDT - 3 years ago

Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting

Mar 28, 2023, 1:00 AM EDT - 3 years ago

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer's and Parkinson's Diseases at AD/PD™ 2023 International Conference

Mar 23, 2023, 4:05 PM EDT - 3 years ago

Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates

Mar 6, 2023, 7:00 AM EST - 3 years ago

Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences

Feb 1, 2023, 7:00 AM EST - 3 years ago

Athira Pharma Announces Publication in Journal of Alzheimer's Disease Highlighting Need for Novel Alzheimer's Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway

Jan 31, 2023, 7:00 AM EST - 3 years ago

Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer

Jan 5, 2023, 7:00 AM EST - 3 years ago

Athira Pharma Provides 2023 Pipeline Outlook

EMILYXCap Mar. 19 at 5:30 PM

$LONA very low attention tape and that is exactly where asymmetry can hide before a pop

0 · Reply

newyork1979 Mar. 18 at 7:16 PM

0 · Reply

Stackdoe101 Mar. 18 at 2:17 PM

$LONA

0 · Reply

Spicy_Trade Mar. 18 at 2:15 PM

SpicyTrade LeonaBio, Inc. ( $LONA ) daily stock analysis https://youtu.be/s1knnYRMF5w?si=Ka0Y8K7hpC7D3CBE

0 · Reply

FoxyDreams Mar. 17 at 11:49 PM

0 · Reply

FoxyDreams Mar. 17 at 8:56 PM

0 · Reply

topstockalerts Mar. 17 at 8:31 PM

Top Gainers PT2 $INLF $KRKR $LONA $LMNX $ISPR

0 · Reply

Jteee Mar. 17 at 7:52 PM

$LONA flying high

0 · Reply

Tradebub Mar. 17 at 7:49 PM

$LONA

0 · Reply

SebNo1234 Mar. 17 at 7:40 PM

$LONA looks wonderful😎🚀🍀👍🚀🚀

0 · Reply

topstockalerts Mar. 16 at 4:16 PM

$LONA Starting to wake up as volume increases. Buyers are getting more aggressive at these levels. Worth keeping this on radar.

0 · Reply

SebNo1234 Mar. 16 at 3:32 PM

$LONA Analysts' price target is $10... so it can still gain a few percent.😎🚀🚀🍀🍀

0 · Reply

PPalisades Mar. 16 at 3:13 PM

$LONA Whats going up here?;)

0 · Reply

BillionerOfKing Mar. 11 at 12:05 AM

$LONA Current Stock Price: $6.58

0 · Reply

SebNo1234 Mar. 10 at 5:00 PM

$LONA

0 · Reply

PatrickVaughn Mar. 10 at 9:36 AM

$LONA low attention setup, quiet accumulation here matters more than the bsoadrd chatter

0 · Reply

SebNo1234 Mar. 9 at 12:36 PM

$LONA

0 · Reply

SebNo1234 Mar. 7 at 6:34 PM

$LONA https://m.aktiencheck.de/news/Nasdaq-LeonaBio_s_Strategic_Pivot_A_New_Identity_for_a_Refocused_Pipeline-19538089

0 · Reply

SebNo1234 Feb. 26 at 2:20 PM

$LONA https://de.investing.com/news/analyst-ratings/cantor-fitzgerald-startet-coverage-fur-leona-bio-mit-overweight-93CH-3362612

0 · Reply

GoCoogs Feb. 26 at 1:52 PM

$LONA LeonaBio initiated with an Overweight at Cantor Fitzgerald

0 · Reply

SebNo1234 Feb. 20 at 10:40 AM

$LONA https://de.investing.com/news/analyst-ratings/mizuho-stuft-leonabio-hoch-aktie-mit-uber-110--kurspotenzial-dank-brustkrebsmedikament-93CH-3350464

0 · Reply

SebNo1234 Feb. 20 at 10:21 AM

$LONA share price Potential of over 110% thanks to breast cancer https://de.investing.com/news/analyst-ratings/mizuho-stuft-leonabio-hoch-aktie-mit-uber-110--kurspotenzial-dank-brustkrebsmedikament-93CH-3350464

0 · Reply

Market Cap	44.57M
Revenue (ttm)	0.00
Net Income (ttm)	-96.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	284,600
Avg Vol	73,932
Day's Range	N/A - N/A
Shares Out	3.94M
Stochastic %K	48%
Beta	2.68
Analysts	Sell
Price Target	$10.00